Related Experiment Video
Updated: Jul 7, 2025
09:46
Accessing the Cytotoxicity and Cell Response to Biomaterials
Published on: July 8, 2021
3.7K
X-Linked Hypophosphatemia: Does Targeted Therapy Modify Dental Impairment?
Anusha Abdullah1, Sabina Noreen Wuersching2, Maximilian Kollmuss2
1Department of Oral and Maxillofacial Surgery and Facial Plastic Surgery, Ludwig Maximilians University, 80337 Munich, Germany.
Journal of Clinical Medicine
|December 23, 2023
Summary
X-linked hypophosphatemia (XLH) causes dental issues. Burosumab therapy shows promise for skeletal problems, but its dental effects require further investigation.
Area of Science:
- Genetics and Endocrinology
- Oral and Maxillofacial Medicine
Background:
- X-linked hypophosphatemia (XLH) is a rare genetic disorder impacting teeth and alveolar bone.
- Dental impairment, including abscesses and dentin defects, often serves as the initial diagnostic sign of XLH.
Purpose of the Study:
- To review the dental characteristics (phenotype) associated with X-linked hypophosphatemia.
- To analyze current and emerging treatment modalities for XLH, with a specific emphasis on their impact on dental health.
Main Methods:
- Literature review summarizing existing studies on XLH.
- Analysis of therapeutic interventions, focusing on Burosumab and its effects on dental manifestations.
- Synthesis of data regarding dental phenotypes and treatment outcomes.
Main Results:
- Genetic discoveries have paved the way for targeted XLH therapies like Burosumab.
- Burosumab has demonstrated efficacy in improving skeletal issues, pain, and phosphate metabolism.
- The impact of Burosumab on dental impairment is still under investigation, with varied findings in recent studies.
Conclusions:
- Burosumab represents a significant advancement in XLH targeted therapy by addressing the underlying pathophysiology.
- Further research is crucial to fully understand and optimize the dental benefits of Burosumab and other treatments for XLH patients.
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
171
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
171
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
161
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
161
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K